Filtricine
Drew Lanza is an accomplished board member and venture capitalist with extensive experience in various sectors. Currently serving as a board member for Smart Coast California and the Santa Catalina Island Company, Drew has also been a founding partner at the Berkeley Catalyst Fund since 2015, where efforts focus on establishing a replicable model for venture capital at UC Berkeley. Additionally, Drew holds the position of Chairman of the Board of Trustees for the San Jose Police and Fire Retirement Fund, facilitating significant initiatives such as Measure G. Previous roles include Chairman Emeritus at Ayla Networks and General Partner at Morgenthaler Ventures, with successful board involvement across numerous companies, including Brion Technologies, which achieved a notable exit of $270 million. Drew's educational background includes degrees in Electrical Engineering from Stanford University and an MBA from Harvard Business School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Filtricine
Filtricine is a clinical-stage biotech company. Filtricine is developing a proprietary targeted nutrients deprivation (TND) technology to help patients living with cancer manage their diseases.